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27, 2012, accepteddjuvant radiation therapy in the management of early stage breast cancer, Hodgkin’s disease, and to a lesser
extent other thoracic malignancies has led to a signiﬁcant improvement in disease-speciﬁc survival. Cardiovascular
disease is now the most common nonmalignancy cause of death in radiation-treated cancer survivors, most often
occurring decades after treatment. The spectrum of radiation-induced cardiac disease is broad, potentially involving
any component of the heart. The relative risk of coronary artery disease, congestive heart failure, valvular heart
disease, pericardial disease, conduction abnormalities, and sudden cardiac death is particularly increased. Over the
years contemporary techniques have been introduced to reduce cardiac morbidity and mortality in radiation-treated
cancer survivors; however, the long-term effects on the heart still remain unclear, mandating longer follow-up.
Awareness and early identiﬁcation of potential cardiac complications is crucial in cancer survivors, with the
management often being quite complex. This review examines the epidemiology of radiation-induced cardiac
disease together with its pathophysiology and explores the available treatment strategies and the potential utility
of various screening strategies for affected cancer survivors. (J Am Coll Cardiol 2013;61:2319–28) ª 2013 by the
American College of Cardiology FoundationAlthough the introduction of radiation therapy (RT) into
the portfolio of therapies used in the management of
thoracic malignancy has led to a signiﬁcant improvement in
disease-speciﬁc survival for patients with early stage breast
cancer, Hodgkin’s disease (HD), and to a lesser extent lung
cancer and some other malignancies involving the thoracic
region, the treatment has seen the emergence of a new
spectrum of cardiovascular disorders induced by radiation
injury. Radiation-induced cardiac disease encompasses a
spectrum of deleterious effects on the heart from pre-clinical
histopathologic ﬁndings in isolation to symptomatic clinical
disease. Multiple studies have shown that these patients
have an increased risk of coronary artery disease (CAD),
congestive heart failure, valvular heart disease, pericardial
disease, and sudden death (1–5). This review examines the
epidemiology of radiation-induced cardiac disease together
with its pathophysiology, therapy, and potential compli-
cating role in the context of cardiovascular interventions.Epidemiology
Given that survival rates for many forms of thoracic malig-
nancy have improved over the past few decades, sufﬁcientCentre, Alfred Hospital, Melbourne, Australia; yHeart Failure
Baker IDI Heart and Diabetes Institute, Melbourne, Australia;
edicine, Monash University, Melbourne, Australia; and the xPeter
r Institute, Melbourne, Australia. The authors have reported that
onships relevant to the contents of this paper to disclose.
ived November 23, 2012; revised manuscript received December
January 8, 2013.time has now passed for the sequelae of radiation-induced
cardiac injury to become clinically evident. Among
Hodgkin’s lymphoma and breast cancer patients treated with
radiotherapy, cardiovascular disease (CVD) is the most
common nonmalignant cause of death (1,6–8). Over the
long term, the beneﬁts of radiotherapy might be partially
offset by cardiac complications. The late effects of irradiation
generally become evident during intervals ranging from 3 to
29 years after treatment (9), usually appearing in the second
to third decade post-therapy (1,2,5,10). Contemporary
radiotherapy techniques such as reduction in doses and ﬁeld
size have been shown to be safe with no increase in disease
relapse in HD (11). However, it is unclear whether such
techniques have reduced the risk of late complications in
magnitude or simply delayed the time to onset. As such,
longer follow-up will be required to determine the pattern
and prevalence of radiation-induced CVD with present
radiotherapy methods.
Hodgkin’s lymphoma is one of the most common cancers
in young adults, with an annual incidence of approximately
3 of 100,000 (5,12,13). Early stage HD has become a highly
curable disease, with survival rates approaching 95%, and
the overall 5-year survival rate is 85% with modern radio-
therapy and chemotherapy used either alone or in com-
bination (13,14). Cardiovascular complications late after
mediastinal radiotherapy is the next most common cause of
treatment-related morbidity after second malignancy in HD
survivors. They account for 25% of mortality in cured
patients (15–17). Myocardial infarction is the most common
cause of cardiac mortality in this patient subgroup (2,18).
Table 1
AR and Excess Ri
Hodgkin’s Disease
Years
Post-Treatment
Aleman et al. (
RR AR
0–5 7.7 6.1
5–10 7.0 10.6
10–15 4.5 10.7
15–20 6.8 28.7
>20 8.3 53.9
AR ¼ absolute risk; RR ¼ relative risk.
Abbreviations
and Acronyms
BNP = B-type natriuretic
peptide
CABG = coronary artery
bypass grafting
CAD = coronary artery
disease
CCT = coronary
computerized topography
CVD = cardiovascular
disease
HD = Hodgkin’s disease
ICD = implantable
cardioverter-deﬁbrillator
LV = left ventricular
MRI = magnetic resonance
imaging
PCI = percutaneous coronary
intervention
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2320The estimated relative risk of
cardiac mortality ranges from 2.2
to 12.7, and the absolute excess
risk ranges from 9.3 to more
than 28 of 10,000 person years of
follow-up (1,2,6,7,10,18,19). An
estimated aggregate incidence of
radiation-induced cardiac dis-
ease is between 10% and 30% by
10 years post-treatment, with up
to 88% of patients demonstrating
asymptomatic cardiac abnormal-
ities (20). Multiple studies have
supported a signiﬁcant increase
in the incidence of CVD in long-
term survivors (1,2,10,19), ex-
tending to increased requirement
for coronary artery bypass grafting
(CABG) (3.2-fold), percutaneous
coronary intervention (PCI) (1.6-
fold), implantable cardioverter-deﬁbrillator (ICD) or pacemaker (1.9-fold), valve surgery
(9.2-fold), pericardial surgery (12.9-fold) (19), and heart
failure (4.9-fold) (21). Moreover, the increase in cardio-
vascular morbidity is accompanied by a clear increase in the
risk of cardiac mortality (Table 1).
Breast cancer is the most common cancer in women, with
1 in 8 women being diagnosed within their lifetime (22).
Breast conservation with post-operative radiotherapy has
become the standard of care of treatment for many women
with early breast cancer and provides overall survival now
equivalent to mastectomy (23). The current 5-year survival
of early stage breast cancer is 95% (22). The largest meta-
analysis exploring the impact of radiotherapy on breast
cancer morbidity and mortality from other causes was con-
ducted by the Early Breast Cancer Trialists Collaborative
Group (24). This study showed that in the absence of any
breast cancer deaths, the 20-year survival was 69.5% among
those randomized to radiotherapy versus 73.8% for control
subjects. Although adjuvant radiotherapy decreased the
annual mortality rate from breast cancer by 13%, the annual
mortality from other causes was increased by 21% (24).
In a further meta-analysis, a signiﬁcant excess of non-
breast cancer-related mortality attributable to CVD wassk of Cardiac Mortality in
Survivors
1) Swerdlow et al. (2) Castellino et al. (10)
RR AR RR AR
1.7 4.6 d d
2.3 10.9 5.1 d
1.9 8.5 12.3 d
4.1 28.9 12.3 d
3.1 22.2 25.0 ddemonstrated (death rate ratio: 1.27, p ¼ 0.0001) (25). Of
note, however, many of the trials included in these studies
employed radiotherapy techniques that would now be
considered suboptimal. Højris et al. (26) assessed the
morbidity and mortality in patients treated with post-
mastectomy radiotherapy with modern approaches and did
not demonstrate a signiﬁcant effect on CVD outcomes,
although follow-up was relatively short. In contrast, data
from the Dutch Late Effects Breast Cancer Cohort showed
a signiﬁcant increase in mortality from CVD in irradiated
patients versus control subjects, with a particularly strong
interaction between smoking and radiotherapy treatment
(27). There are conﬂicting data with regard to increased risk
of left- versus right-sided breast cancer with adjuvant
radiotherapy. Correa et al. (28) retrospectively studied 961
patients and found that 46 left-sided and 32 right-sided
previously treated patients had undergone a stress methox-
yisobutylisonitrile at a median of 12 years post-radiotherapy.
Positive studies were found in 59% of patients with left-
sided treated cancer versus 8% of patients with right-sided
cancer (p ¼ 0.01) (28). Similarly, in a large study of 4,456
women, Bouillon et al. (29) also found a signiﬁcantly
increased long-term risk of dying from cardiac disease
among women treated with chest wall radiotherapy for
a left-sided breast cancer compared with right-sided.
Association studies have also examined the relationship
between radiotherapy and CVD in pediatric cohorts and
patients with lung cancer. Observations made in the pedi-
atric population have provided unequivocal proof that
radiotherapy is associated with increased risk of cardiovas-
cular mortality. Tukenova et al. (30) studied 4,122 cancer
survivors, <15 years of age at time of recruitment, with
a mean follow-up of 27 years. The standardized mortality
ratio for death was 4.2 compared with the general population
and 5.8 for cardiac death. The relative risk for death was
proportional to radiation dose (relative risk: 3 to 25, for 1 to
4.9 Gy to >15 Gy, respectively) (30). There have been
multiple case reports in radiation-treated children as young
as 12 years old suffering sudden cardiac death with autopsy-
proven critical left main stenosis (31). Cardiac injury is less
commonly reported in patients who receive RT for lung
cancer, because most patients who receive RT for unre-
sectable lung cancer do not live long enough to experience
late-term toxicities or already have signiﬁcantly reduced
cardiopulmonary reserve (32).
Developments in Radiotherapy
Historically, thoracic radiotherapy techniques for cancer
treatment involved relatively high doses being delivered to
a high volume of the heart, with the dose varying depending
on the cancer targeted. Before the late 1980s, Hodgkin’s
lymphoma patients received between 35 and 45 Gy over the
dedicated treatment regime. In more recent years, doses of
30 Gy have been shown to yield similar results, and in
combined modality treatment this has become the standard
Table 2 Effects of Radiation Therapy on the Heart
Vascular
Coronary artery disease
Microvascular dysfunction
Structural
Valvular heart disease
Mitral stenosis and insufﬁciency
Aortic stenosis and insufﬁciency
Pericardial disease
Conduction system disease
Myocardial
Systolic dysfunction/systolic heart failure
Diastolic dysfunction/heart failure with preserved ejection fraction
Restrictive cardiomyopathy
Myocardial ﬁbrosis/scar
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2321of care in most countries (11,33). Lower doses of 20 Gy in
combined modality treatment are currently under investi-
gation, with encouraging preliminary results (11). In the
breast cancer population, up to 45 to 50 Gy of radiation
might be used in the treatment of cancers at high risk
of regional recurrence (26,29). In Hodgkin’s survivors,
Schellong et al. (34) found that the cumulative incidence of
cardiac disease after 25 years exposure to a mediastinal
radiation dose of 36 Gy was 21%, signiﬁcantly decreasing
to 6% and 5% to those exposed to 25 Gy and 20 Gy,
respectively.
Over the years, improved irradiation techniques have been
introduced to minimize irradiation to the heart; however, the
existence or magnitude of the residual risk is still uncertain.
Techniques to further reduce cardiac exposure such as
image-guided therapy; 3-dimensional treatment planning;
respiratory gating; and intensity modulated RT, aiming to
deliver radiation more precisely to the tumor while relatively
sparing the surrounding normal tissue, show promise and
are still under investigation (20,35,36). Data from Campbell
et al. (36) support further targeted ﬁeld reduction from
involved-ﬁeld RT to involved-nodal RT as a component of
adjuvant therapy for early HD and have found no statistical
difference in progression-free survival and overall survival at
10 years. Other modern techniques employed to minimize
radiation exposure include cardiac shielding (with lead
blocks), reduced fraction size (<2 Gy/day), reduced total
dose of radiation (<30 Gy/day), and relative ﬁeld weighting
(aimed to minimize overexposure to the anterior medias-
tinum) (20,37). The clear goal is to decrease the intensity of
therapy without sacriﬁcing long-term disease control.
Pathophysiology and Histopathology
Irradiation can damage all cells, both cancer cells and healthy
cells, and can affect blood vessels of all sizes. Radiation
therapy causes an increase in capillary wall permeability,
with dilation of vessels leading to the characteristic radiation
erythema. Radiation treatment causes direct damage to
blood vessels by the generation of reactive oxygen species
that disrupt DNA strands leading to an inﬂammatory
cascade (38). The same process occurs in the vasculature of
the heart. This inﬂammatory cell inﬁltrate disturbs the
ﬁltration properties of the endothelium, and the basement
membrane of the capillary wall thickens as a result of
collagen deposition and ﬁbrosis (16). Endothelial dysfunc-
tion is believed to be a precipitating factor in the develop-
ment of cardiac sequelae (39) and is most likely a
combination of impaired endothelial function, stimulation of
growth factors, and eventual ﬁbrosis (40). Analogous to
atheromatous plaques, however differing in their microvas-
cular location, there is progressive hypoperfusion with
microvascular thrombosis and ischemia, with eventual small
vessel occlusion and cell death. The pathohistologic hall-
marks include diffuse ﬁbrosis of the interstitium of the
myocardium and arterial lumen narrowing (41).Thoracic RT can affect all of the structural components
of the heart, including the pericardium, myocardium, heart
valves, coronary arteries and capillaries, and conducting
system (2,5,21) (Table 2). Pericarditis is the typical acute
manifestation of radiation injury, whereas chronic pericardial
disease, CAD, valvular heart disease, systolic and diastolic
cardiomyopathy, and conduction abnormalities (complete
heart block, sick sinus syndrome, prolonged QTc) might
manifest years or even decades after treatment exposure
(5,9,19). Several risk factors for the development of radiation-
associated cardiotoxicity have been identiﬁed (Table 3).
Systemic chemotherapy, particularly anthracycline agents
and trastuzumab (even more potent in combination), can
also have a dose-dependent synergistic impact on cardiac
dysfunction (20,42).
Pericardial disease. Acute radiation pericarditis might be
one of the earliest cardiac complications of radiotherapy and
was historically the most common cardiovascular manifes-
tation of irradiation therapy, typically manifesting a few
weeks after treatment. Modern methods of implementation,
including lower doses (including equally weighted anterior
and posterior beams) and shielding methods (like subcarinal
blocking) have decreased the incidence from 20% to 2.5%
(43,44), with the incidence being proportional to dose and
treatment volume (17). Pericarditis is usually self-limiting,
however, 10% to 20% of patients develop a chronic or
constrictive pericarditis 5 to 10 years after treatment (16).
Associated pericardial effusions are characterized by ﬁbrous
adhesions, high protein count, and an increase in serum
inﬂammatory markers. Chronic pericarditis might occur
even if the patient did not experience an acute event.
Fibrotic fusion and thickening of the visceral and parietal
layers in the presence of a tense effusion in the free peri-
cardial space is referred to as effusive-constrictive pericarditis
and has been well-described in radiation-treated cancer
survivors (45,46).
CAD. Pathologically, vascular radiation injury is accom-
panied by an increase in capillary wall permeability, the
generation of reactive oxygen species, and activation of an
inﬂammatory cascade (38). This subsequently leads to
Table 3 Risk Factors for Radiation-Induced Cardiotoxicity
Total dose >30–35 Gy
Higher dose/fraction >2 Gy/day
Field size (volume of heart irradiated)
Relative ﬁeld weighting (anterior/posterior positioning)
Presence of tumor next to the heart
Younger age at exposure
Time since exposure
Type of radiation source (cobalt)
Cardiotoxic chemotherapy (e.g., anthracycline)
Other cardiovascular risk factors (e.g., diabetes, smoking)
Technique (reduced with CT plan)
Adapted, with permission, from Gaya et al. (16) and Carver et al. (20).
CT ¼ computed tomography.
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2322intimal proliferation with collagen deposition and ﬁbrosis
(16). As such, initial endothelial dysfunction is believed to
be a key factor in the development of cardiac sequelae (39).
In the case of CAD, the stenoses might be due to intimal
proliferation, damage to the intima, or atherosclerotic lesions
(9). This initiates a cascade of events that is typical of
atherosclerosis, including replacement of damaged cells with
myoﬁbroblasts along with platelet deposition. In vitro
studies have also revealed the pro-thrombotic effect of
radiation associated with higher release of von Willebrand
factor which can provoke and contribute to coronary
thrombosis (47,48). Ultimately, the mechanism involved in
plaque formation is thought to mirror spontaneous athero-
sclerosis; however, plaques in irradiated patients have been
found to be more ﬁbrous with a decreased lipid component
(17,49–51). Ostial stenoses are typical for radiation-induced
CAD. Macroscopically, there is a signiﬁcantly higher inci-
dence of severe left main disease, followed by ostial right
coronary artery and left anterior descending artery stenoses
correlating with the anatomic location of radiation treatment
(9). In general, the lesions are consistently longer, more
proximal, smoother, concentric, and tubular (9). The inci-
dence of radiation-induced CAD is increased by the stan-
dard cardiac risk factors. Hull et al. (52) studied 415 patients
post-RT for Hodgkin’s lymphoma and found that 10.4% of
patients developed signiﬁcant CAD (deﬁned as having
history of myocardial infarction/CABG/>75% luminal
stenosis on angiography or autopsy) at a median of 9 years of
follow-up.
Myocardium. The lack of myocyte cell division makes the
myocardium itself relatively radiation resistant. However,
diffuse interstitial ﬁbrosis occurs after relatively low doses
of radiation through microvascular insufﬁciency and
ischemia, involving damage to the capillary endothelial cells
(53,54). The result is an alteration in the compliance of
the myocardium, leading to both systolic and diastolic
dysfunction. Most patients with myocardial involvement
have some degree of interstitial ﬁbrosis (55), typically
developing at radiation doses above 30 Gy. It has been
shown that diastolic dysfunction is seven-fold more commonin individuals treated with thoracic radiotherapy popula-
tion compared with community control subjects, and the
presence of diastolic dysfunction is associated with stress-
induced ischemia, a worse prognosis, and event free
survival (56).
Valvular dysfunction. Radiotherapy might directly damage
cardiac valves and surrounding myocardium, leading to
ﬁbrotic thickening, valvular retraction, and late calciﬁcation
(5). The incidence of valvular dysfunction has been reported
to increase during the second decade after mediastinal
radiotherapy for HD (5). Wethal et al. (5) found that, of 116
patients observed approximately 10 years after treatment,
36 (31%) demonstrated moderate valvular regurgitation in
40 valves, primarily either the aortic or mitral valve, whereas
none had evidence of stenosis. Interestingly, in the same
cohort 39% of patients still available for follow-up 12 years
later had developed aortic stenosis, including some of a
moderate to severe degree (35%) (5). The valves were
found to be thicker with reduced leaﬂet motion and calci-
ﬁcation (5). These results suggest that valve retraction is
the predominant early change that causes regurgitation and
that it might take in excess of 20 years for the valves to
become signiﬁcantly thickened, calciﬁed, and stenotic. It is
hypothesized that a higher pressure system on the left side of
the heart compared with the right accounts for why the
mitral and aortic valves are affected more than the pulmo-
nary and tricuspid. Multiple studies have supported the
higher incidence of aortic and mitral valve disease (4,5,57).
Consistent with these observations, another study found
that, of asymptomatic patients previously treated with at
least 35 Gy of radiation, 6% had clinically signiﬁcant
dysfunction, and 26% had >grade II aortic regurgitation.
This equated to a 34-fold increased risk compared with
the Framingham population (4). Also, 26% demonstrated
marked calciﬁcation of the aortomitral curtain (4).
Conduction system. Abnormalities along the entire
conduction system have been described in the setting of
radiotherapy, including varying degrees of atrioventricular
block, sick sinus syndrome, prolonged QTc, supraventricular
arrhythmias, and ventricular tachycardia (53,58). Right
bundle branch block is more commonly observed than left
bundle branch block post-RT, likely due to higher radiation
exposure of the right ventricle due to its anterior location.
Ventricular ectopy might occur in up to 50% of patients
exposed to mediastinal irradiation, often secondary to
ventricular ﬁbrosis (53,58). Crestanello et al. (59) found
a high post-operative prevalence of conduction disease after
valvular surgery in this patient cohort, with 27% of patients
requiring permanent pacemaker placement. Dysfunction of
the autonomic nervous system, leading to persistent tachy-
cardia, loss of circadian heart rhythm, and respiratory phasic
heart rate variability has also been described after irradiation
(60). The latter clinical picture is similar to heart transplant
patients who have a denervated heart (60). Persisting
tachycardia might further increase the patient risk of
developing a tachycardia-mediated cardiomyopathy.
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Long-term cardiac injury after radiation treatment depends
on several factors, including: total radiation dose; dose of
radiation fraction/day; amount and areas of the heart treated;
presence of tumor within or adjacent to the heart; left-sided
tumors; and the use of concomitant cardiotoxic chemo-
therapeutic drugs such as the anthracyclines and trastuzu-
mab (16,20,61). In particular, newer approaches to the
delivery of more targeted and lower-dose therapy will likely
lead to a reduction in the frequency of the cardiac compli-
cations of radiotherapy. Conventional risk factors for CAD,
including age, increased body mass index, hypertension,
hypercholesterolemia, diabetes mellitus, smoking, preexist-
ing CVD, and a positive family history, also compound the
risk. Going forward, diagnosis of cancer might also lead
patients to adopt unfavorable lifestyle changes such as
decreased physical activity and weight gain, which might
concomitantly reduce cardiovascular reserve and heighten
the risk of CVD.
Cardiac Evaluation of the
Post-Radiotherapy Patient
A strategy for prolonged cardiological follow-up and cardiac
screening is mandatory in cancer patients who have received
irradiation to facilitate early identiﬁcation of cardiac related
complications. As outlined in the following text, strategies
for early detection likely provide the best approach in which
to reduce the morbidity and mortality caused by radiation-
induced heart disease. Before radiotherapy, a comprehen-
sive baseline evaluation including a detailed cardiovascular
history, cardiac examination, risk factor proﬁling, and echo-
cardiography should be performed. In particular, the echo-
cardiographic examination should include a thorough
investigation of both systolic and diastolic function. Accord-
ingly, aggressive management of any cardiac risk factors
should be implemented. Surveillance monitoring is para-
mount, because the timing of medical or surgical intervention
can be crucial for optimal patient outcomes. In the pre-
operative setting, smoking cessation, pulmonary rehabilita-
tion, and prophylactic draining of pleural effusions might be
beneﬁcial to minimize the frequent and problematic post-
operative pulmonary complications (62).
There is a paucity of data to support the optimal method
and frequency of screening post-radiotherapy patients.
Currently only expert opinion and consensus-based guide-
lines for cardiac follow-up are available. In 2006, the
American Society of Clinical Oncology submitted screening
recommendations for both chemotherapy and radiotherapy-
induced cardiac and pulmonary late effects (20). The
document was not approved, due to lack of direct evidence
with regard to the utility, beneﬁt, and harm of screening
(20). Beyond this, Byrd and Mendes (63) proposed
screening echocardiography 10 years after treatment in the
asymptomatic cohort. In addition, the American College of
Radiology and National Comprehensive Cancer Networkrecommends a baseline stress echocardiogram at 5 to
10 years and 10 years, respectively, with 1 to 3 yearly glucose
and lipid proﬁle review (64,65). Heidenreich and Kapoor
(53) have recommended that stress testing should begin
5 years post-irradiation therapy. The Children’s Oncology
Group has also developed guidelines for the surveillance
of pediatric patients, recommending second yearly trans-
thoracic echocardiograms for those below 5 years of age at
treatment (once yearly if concomitant anthracycline therapy)
(66). For children >5 years at age of treatment, recom-
mendations were based on radiation dose, with children
exposed to <30 Gy requiring 5 yearly echocardiograms and
second yearly for those exposed to >30 Gy (once yearly if
moderate-dose anthracyclines were needed) (66).
It might be reasonable to follow a more conservative
follow-up approach in the absence of symptoms. We
propose that cardiac screening should commence as early as
5 years post-cessation of radiation treatment or after the age
of 30, whichever occurs ﬁrst. We recommend annual
specialist review, potentially in a Late Effects or Survivorship
Clinic, given the constellation of other sequelae that might
manifest, with early referral to a cardiologist should either
asymptomatic structural or functional dysfunction be evident
or if symptoms arise. In addition to an annual consultation
and a meticulous cardiac examination, the focus of screen-
ing should ideally incorporate noninvasive, radiation-free
modalities in the ﬁrst instance. Furthermore, it is para-
mount that any woman who has had thoracic radiation
and/or anthracycline treatment have at least their ﬁrst preg-
nancy monitored in a tertiary referral center and be assessed
by a cardiologist in their second trimester, because under-
lying cardiac failure can be exposed during this time (67).
At 5 years, then annually. B-type natriuretic peptide
(BNP) and troponins might be useful serum biomarkers
that might be able to act as early and perhaps pre-clinical
markers of myocardial damage. This has been more widely
researched in chemotherapy patients; however, Nellessen
et al. (54) also evaluated plasma levels of troponin and BNP
up to 6 weeks post-RT. Plasma levels of both biomarkers
increased over the study period, although without measured
impairment in left ventricular (LV) function. This ﬁnding
supports the potential use of biomarkers in screening post-
treatment to potentially identify high-risk patients. In
addition to BNP and troponins, blood tests such as fasting
serum glucose and lipid proﬁles should also be reviewed
annually. Annual electrocardiography is also a simple
investigation that might alert the treating physician to the
development of progressive conduction abnormalities. A
24-h ambulatory Holter monitor might also be warranted,
depending on the clinical scenario. In one study by Larsen
et al. (58), 7% of childhood cancers survivors (mean age
15 years) were found to have ventricular tachycardia on 24-h
Holter monitor. Given the sporadic and variable frequency
of ventricular arrhythmias, this study might have under-
estimated the prevalence of ventricular arrhythmias in
survivors of childhood cancer.
Figure 1 Cardiac Computed Tomography Images
Cardiac computed tomography images from a 56-year-old man, 27 years
post-mantle irradiation for Hodgkin’s disease. Images demonstrate calciﬁed
aortomitral curtain and aorta (A), and mitral valve annulus (B).
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2324As outlined in the preceding text, the key late cardio-
vascular sequelae of thoracic irradiation are the result of
coronary, myocardial, and valvular pathology. Most of these
complications can be evaluated for using combined rest and
stress echocardiography. This approach enables the clinician
to assess LV systolic function, diastolic function, valvular
function, pericardial integrity, and regional wall abnormali-
ties, both at rest and with exercise. When possible, stress
echocardiography should be chosen over a stress thallium/
methoxyisobutylisonitrile for the radiation-free and func-
tional advantages, particularly relevant in this patient cohort.
Vigilant screening for athletic participation might also
be an important consideration in the pediatric cancer group.
In the setting of documented arrhythmias and to further
risk-stratify patients, cardiac magnetic resonance imaging
(MRI) is an extremely valuable modality to further assess for
regional scar, potentially serving as a substrate for ventricular
arrhythmias. In patients with nonischemic cardiomyopathy,
late gadolinium enhancement on cardiac MRI has been
shown to strongly predict adverse cardiac outcomes such as
hospital stays for heart failure, appropriate ICD ﬁring, and
death (68). There is a growing body of published data
supporting a potential role for cardiac MRI and late gado-
linium enhancement in the risk stratiﬁcation and prognos-
tication of patients with cardiomyopathy (68–70), which
might have further value in determining the need for device
therapy.
Furthermore, cardiac MRI is a highly sensitive modality
that potentially provides clinical information beyond the
capability of echocardiography, particularly with regard to
tissue characterization. Cardiac MRI is particularly useful
to assess for regional and, more recently, diffuse myocardial
ﬁbrosis with delayed gadolinium enhancement and T1
mapping respectively, with increasing evidence that T1
mapping correlates with diffuse ﬁbrosis and diastolic dys-
function (71,72). Thereby, cardiacMRImight be particularly
valuable to diagnose asymptomatic diastolic dysfunction and
possibly guide the timing of initiation of anti-ﬁbrotic agents
like angiotensin-converting enzyme inhibitors (ACEI) and
aldosterone inhibitors. Cardiac MRI might also be useful
to evaluate possible diastolic dysfunction in the patient
population that cannot undergo tissue Doppler imaging,
limited by a heavily calciﬁed cardiac skeleton (Fig. 1), mitral
stenosis, or mitral valve replacement.
Coronary computerized topography (CCT) can non-
invasively detect and quantify obstructive coronary artery
stenoses. Novel prospective gating techniques have signiﬁ-
cantly reduced radiation dose, making cardiac computed
tomography an increasingly attractive and complementary
investigative tool for cancer survivors. In the general pop-
ulation, the coronary calcium score is particularly useful
(with very little radiation exposure) to predict coronary artery
stenosis and cardiac events and adds prognostic value to the
Framingham risk score. Yeboah et al. (73) have shown that
the coronary calcium score provides superior discrimination
and risk reclassiﬁcation compared with other risk markers inintermediate-risk individuals. However, its utility in the late
effects patient cohort is still to be determined. Rademaker
et al. (74) retrospectively evaluated the CCT ﬁndings of
9 HD survivors, treated with radiotherapy 12 to 35 years
ago. This pilot study showed that 8 of the 9 patients were
found to have at least mild atherosclerosis, 66% had calcium
scores within the 90th percentile for their age, and 2 patients
proceeded to coronary angiography (1 requiring PCI, and 1
requiring CABG) (74). Patients with the lowest radiation
dose and shortest interval since radiotherapy had minimal or
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2325no ﬁndings of CAD. At this early stage, however, we do not
recommend that baseline screening stress echocardiography
should be substituted for CCT. However, this is certainly
a potential focus for further research.Therapy
Acute and chronic pericarditis. As outlined in the
preceding text, acute pericarditis is relatively uncommon
with the use of more contemporary thoracic radiotherapy
strategies. Similar to other forms of acute pericarditis,
patients might present with fever, pleuritic chest pain,
dyspnea, and tachycardia. Typical clinical, electrocardio-
graphic, and biochemical features might be present.
Transthoracic echocardiography should be performed to
exclude tamponade. Cardiac MRI might also be useful to
conﬁrm the diagnosis and establish the degree of pericardial
thickening along with an assessment for myocardial in-
volvement. Treatment includes the use of nonsteroidal anti-
inﬂammatory agents. Pericardiocentesis might be indicated
if there is an associated large pericardial effusion and if the
patient is signiﬁcantly hemodynamically compromised.
Pericardectomy might be required for constrictive pericar-
ditis. It is important to exclude other etiologies in the setting
of recurrent pericardial effusion such as infection, tumor
invasion or recurrence, and hypothyroidism, which might be
seen after mantle irradiation. Constrictive pericarditis has
been described as a marker for greater radiation injury to
the heart, associated with diastolic dysfunction and high
mortality (58). Early pericardial stripping might be supported
at the time of planned cardiac surgery to improve post-
operative cardiac physiology (62).
CAD. In the setting of ﬂow limiting disease of the major
epicardial coronary arteries, most lesions have been found
to be amenable to treatment with either CABG or PCI
dependent upon the speciﬁc anatomy. Some early studies
have suggested that percutaneous angioplasty seems to have
a higher rate of restenosis (75); however, there are no data to
date incorporating outcomes of newer, second-generation
drug-eluting stents. A study conducted by Schomig et al.
(76) found signiﬁcant bare-metal stent restenosis at 6-month
follow-up (86%) in patients with radiation-induced CAD
(p < 0.001) compared with control subjects (76). The group
subjects were also found to have signiﬁcantly narrower
coronary lumen diameters (1.0  0.6 mm vs. 1.9  0.9 mm,
p < 0.001). Caution with appropriate patient selection must
be exercised for PCI, given that certain post-irradiation
complications might preclude surgical candidature for failed
PCI. Of note, the internal mammary arteries might be
chronically scarred or more friable, making them unsuited for
use in bypass grafting. In conjunction, the presence of
damaged target vessels might add increasing complexity and
risk in patients undergoing CABG (77,78). In one study, the
internal mammary artery was an appropriate conduit less than
one-half the time, routinely harvested by the same authors in
their standard practice (62). Routine angiography of theinternal mammary arteries might be useful to guide conduit
utility and subsequent treatment options.
To date there are few studies, mostly with small patient
numbers, on cardiac surgical outcomes and the post-
operative course in this speciﬁc patient population. Siregar
et al. (79) showed that previously treated patients for
Hodgkin’s lymphoma had relatively good early post-
operative outcome with a 1-year survival of 86%; however,
the long-term survival at 4 years was only 46%. The most
common post-operative complication after cardiac surgery
(operations included: CABGs, valvular repair, valvular
replacement) was atrial ﬁbrillation, however, with a slightly
higher incidence than described by large databases in the
general population [33% vs. 20%] (79,80). In the post-
operative setting these patients are also at increased risk of
pulmonary complications, particularly pleural effusions,
pneumonia, and respiratory insufﬁciency, due in part to the
presence of pre-existing radiation-induced lung disease and
smoking (62,79). Thus pre-operative smoking cessation
assumes even greater importance in this patient cohort.
The presence of diastolic dysfunction is another challenging
issue in this patient group, with high left atrial pressures
contributing to pulmonary congestion, thereby increasing
post-operative morbidity. The largest study performed by
Chang et al. (62) included 70 patients with previous HD.
These authors found that extensive exposure of the heart
to radiation increased perioperative morbidity and decreased
both short- and long-term survival. The cardiac risk factors
included higher central venous pressure, higher left atrial
pressure, and lower LV mass (62). Increased central venous
pressure as a risk factor also suggests that concomitant right
ventricular dysfunction is a complicating factor, and in
particular the anterior location of the right ventricle makes it
vulnerable to dysfunction post-radiotherapy.
As such, it is clear that, for patients with a prior history
of chest irradiation in whom cardiothoracic surgery is
contemplated, full consideration should be given to the
potential impact of alterations in the structure and function
of the skin, mediastinal tissues, lungs, intra-thoracic vessels,
and the heart per se require careful consideration (59,81).
On balance, an appropriate choice of surgical versus percu-
taneous interventions balancing the relevant risk/beneﬁt
ratio of each approach can then be offered to the patient in
the setting of the speciﬁc clinical context.
Conduction disturbance. A permanent pacemaker is
indicated in the setting of high-degree block or symptomatic
sick sinus syndrome, following the routine American
College of Cardiology/American Heart Association guide-
lines. Additionally, after a life-threatening arrhythmia or
aborted sudden cardiac death, an ICD is indicated for
secondary prevention, upon exclusion of ischemia. For some
patients, an electrophysiological study and ventricular
tachycardia ablation might be useful.
Valvular dysfunction. As outlined in the preceding
text, aortic and mitral valve regurgitation and stenosis
are well-recognized complications of thoracic irradiation.
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2326Crestanello et al. (59) were one of the ﬁrst groups to
investigate whether conventional reparative techniques could
be applied to irradiation related valvular disease. These
investigators found that the durability of valve repair in long-
term survivors was limited, because severe dysfunction
developed in one-third of the patients and with reoperation
being required in 16% (59). Accordingly, valve replacement
might be preferable to valve repair when considering long-
term cardiovascular outcomes. In some cases of severe
aortic stenosis with signiﬁcant extracardiac late sequelae of
radiotherapy, transcatheter aortic valve implantation might
be the best treatment option.
Heart failure. Although no speciﬁc therapies for the treat-
ment of radiation-induced heart failure have been identiﬁed,
therapy of systolic heart failure should follow American
College of Cardiology/American Heart Association guide-
lines, with slow upward titration of ACEI, beta blockade, and
aldosterone inhibitors, particularly in patients with reduced
LV systolic function. In patients with diastolic dysfunction,
the principles of treatment broadly mirror those of patients
with heart failure with preserved ejection fraction. Although
no treatment has been shown to convincingly improve
morbidity and mortality in patients with heart failure with
preserved ejection fraction (82), diuretic agents and, more
recently, exercise training might be introduced to improve
symptoms (83). Hypertension, sinus rhythm, and myocardial
ischemia must also be optimized. The same indications for
insertion of ICD cardiac resynchronization therapy should
apply to patients with radiation-induced heart failure and
might additionally prolong survival. If signiﬁcant subcuta-
neous skin involvement is observed as a late effect of thoracic
irradiation, a sub-pectoral approach for device implantation
might be necessary to avoid poor wound healing and infection.
In the instance of refractory heart failure, temporary inotropic
support for periods of decompensation might be needed. In
patients with refractory heart failure the use of LV assist
devices and heart transplantation might be considered;
however, the decision with regard to the appropriateness of
such therapies clearly requires multidisciplinary input,
particularly from oncologists.
Heart transplantation. For a small patient subgroup
with biventricular dysfunction, calciﬁed cardiac skeleton
(Fig. 1), previous open-heart surgery, and restrictive or
constrictive hemodynamic status, heart transplantation
might be the only possible and reasonable treatment option.
The largest reported study to date was conducted by Uriel
et al. (84). This was a retrospective study of 9 patients with
radiotherapy induced cardiac disease who underwent ortho-
tropic heart transplantation. Of these patients, there were 3
in-hospital perioperative deaths, 3 second cancers, and 3 life-
threatening infections. Five of the 9 patients (56%) were still
alive at a mean follow-up of 10 years post-transplantation
(however, 2 with a second cancer) (84). Orthotropic heart
transplantation also raises the question of potential cancer
recurrence in an immunosuppressed population, with a
paucity of data in this area to date.Future research. Large prospective studies still need to
be conducted to explore the beneﬁt of prophylactic treat-
ment strategies in asymptomatic patients. For example,
the effect of statins, ACEI, or aldosterone inhibitors in
asymptomatic radiation-treated cancer survivors to slow/halt
accelerated atherosclerosis, myocardial dysfunction, or
myocardial ﬁbrosis is not yet known. The clinical beneﬁt of
such pharmacological agents in those both with and without
additional cardiac risk factors is of particular clinical interest.
The impact of newer-generation drug-eluting stents on
in-stent restenosis and particularly stent thrombosis in this
patient cohort still needs to be clariﬁed. And clearly, the
long-term effects of contemporary and reﬁned radiotherapy
techniques mandate further analysis with time.
Conclusions
It is clear that thoracic radiation, particularly as administered
with older treatment paradigms, increases cardiovascular-
related mortality in the long term. Presently, the utility and
optimal strategy for screening is uncertain. Future prospec-
tive long-term studies are needed to directly determine the
efﬁcacy of screening asymptomatic cancer survivors to help
establish guidelines. However, given the high incidence of
such complications, we believe the development of a uniform
approach to be potentially beneﬁcial. The use of noninvasive,
non–radiation-based techniques such as echocardiography
and cardiac MRI provide an opportunity for regular assess-
ment of the heart for the myocardial, valvular, and pericardial
complications of thoracic irradiation. In conjunction, serial
stress echocardiography could provide a useful means for the
detection of developing ﬂow-limiting coronary lesions. The
role of preventive therapies is uncertain at this time; however,
aggressive risk-factor reduction should be adopted according
to published guidelines. Taken together, it is likely that the
incidence of the late sequelae of thoracic irradiation might
continue to rise for some time, reﬂecting the prior use of this
form of adjunctive therapy in patients with malignancy.
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